iarjaccIARJACCIARJACC2709-1880https://doi.org/10.47310/iarjacc.2021.v02i02.012Dexamethasone versus Methylprednisolone Clinical Efficacy in Combating Cytokine Storm Associated Severe Acute Respiratory Distress Syndrome in Mechanically Ventilated Covid-19 Infected Critically Ill PatientsHananFarhan EyadehAlmassarwehWalaaShaher AhmadArabiatMadleenKhalid MohammadNasserAmjadTareqHamadeenPharmacist; 2Internal Medicine. King Hussein Medical Hospital, King Abdullah II St 230, Amman 11733, Jordanian Royal Medical ServicesObjectives: After the large UK randomized controlled trial (RECOVERY Trial), it seems that glucocorticoids are the only cost-effective intervention that is associated with positive major clinical impacts. However, there is still a paucity of information guiding glucocorticoid agents and dose regimens. The present study aims to compare the clinical impacts of two proposed steroidal agents across two investigated dose regimens on the moderate-severe mechanically ventilated critically ill COVID-19, infected patients. Methods: A single-center, observational, retrospective study was conducted on all mechanically ventilated critically I'll COVID-19 infected patients that were admitted into the intensive care units (ICUs). Parametric data were analyzed by using the One-Way ANOVA Test while non-parametric data were analyzed by Chi Square or Kruskal–Wallis Tests. The primary outcome of our study was to compare the major clinical impacts of admission days and mortalities. Results: The average age of our whole study cohort was 59.80±10.74 years, significantly, males were distributed in the study in M: F ratio of approximately 2.42: 1. Overall 28-day ICU mortality was detected in 136 (55.97%) during an average of 13.40±4.79 days and 19.67±6.81 days of the ICU and hospital stay days, respectively. The comparative prognostic biochemical indicators and the variations of body temperature were significantly lower in higher versus standard corticosteroidal dose regimens. Conclusion: In conclusion, higher dose regimens of either Dexamethasone (12 mg/day) or Methylprednisolone (80 mg/day) have a significantly higher positive clinical impact compared with lower dose regimens of either Dexamethasone (6 mg/day) or Methylprednisolone (40 mg/day). Individually, Methylprednisolone 40 mg/day has superior positive clinical impacts over Dexamethasone 6 mg/day at the lower Cs level while at the higher Cs level, Dexamethasone 12 mg/day has superior positive clinical impacts over Methylprednisolone 80 mg/day.